Features

Learn more about how the risk of HDFN in subsequent pregnancies is affected if the infants have different fathers.

Learn more about the potential risks of fetal movement during an intrauterine transfusion and what can be done to help.

RhIG is only effective if it is administered prior to sensitization, so in some cases, it may not be a viable treatment option.

Deciding when to stop IUTs requires balancing the risks of continuing the treatment versus the risks of delivering a premature baby.

Learn more about how red blood cells are “washed,” making them safe for transfusion and reducing the risk of complications.

Learn more about when a baby receives the most maternal antibodies during pregnancy and how the antibodies are transferred to the fetus.

Learn more about how HDFN is diagnosed and how to advocate for earlier HDFN testing during your pregnancy.

Learn more about how keeping a journal during your pregnancy can help your mental health and restore some peace of mind.

Learn more about why donated blood is so important for fetuses and infants with HDFN, especially those with rare blood types.

Learn more about how the prevalence and severity of HDFN can vary based on racial, genetic and socioeconomic differences.